A pilot transcriptomic study of a novel multitargeted BRT regimen for anti–MDA5 antibody-positive dermatomyositis: improving survival over conventional therapy

BackgroundAnti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis (MDA5-DM) is associated with severe outcomes, primarily due to rapidly progressive interstitial lung disease (RP-ILD), which is often refractory to standard therapies such as calcineurin inhibitors (e.g., tac...

সম্পূর্ণ বিবরণ

গ্রন্থ-পঞ্জীর বিবরন

প্রধান লেখক:	Moe Tokunaga, Yu Nakai, Yoshiharu Sato, Mitori Hiratsuka, Yoshinori Matsumoto, Takeshi Nakatsue, Takako Saeki, Takatsune Umayahara, Jun Wada, Yoshinobu Koyama
বিন্যাস:	Artigo
ভাষা:	Inglês
প্রকাশিত:	Frontiers Media S.A. 2025-08-01
মালা:	Frontiers in Immunology
বিষয়গুলি:	anti-MDA5 antibody-positive dermatomyositis (MDA5-DM) JAK inhibitor baricitinib rituximab multitargeted treatment IFN signature
অনলাইন ব্যবহার করুন:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1568338/full
ট্যাগগুলো:	ট্যাগ যুক্ত করুন কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!